Graz

Futó vizsgálatok

• Fut, nem toboroz

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· 3. fázis· Forrás

• Fut, nem toboroz

  Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

  NCT05399992· Forrás

• Fut, nem toboroz

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· 3. fázis· Forrás

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

  NCT05562934· 2. fázis· Forrás

• Lezárult

  Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

  NCT04948333· 3. fázis· Forrás

• Lezárult

  Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

  NCT04541589· 2. fázis· Forrás

• Leállították

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· 3. fázis· Forrás

• Lezárult

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· 3. fázis· Forrás

• Leállították

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· 3. fázis· Forrás

• Lezárult

  Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· 2. fázis· Forrás

• Lezárult

  The Gilenya Pregnancy Registry

  NCT01285479· Forrás